<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741711</url>
  </required_header>
  <id_info>
    <org_study_id>2019PI094</org_study_id>
    <nct_id>NCT04741711</nct_id>
  </id_info>
  <brief_title>AMBulatory UltraSound for Heart Failure Management</brief_title>
  <acronym>AMBUSH</acronym>
  <official_title>Impact of Ultrasound-guided Therapeutic Management of Ambulatory Patients With Heart Failure : An Open-label Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AMBUSH study is a multicenter randomized, controlled, open-label clinical trial (PROBE&#xD;
      (Prospective Randomized Open Blinded End-point) type).&#xD;
&#xD;
      The main objective of AMBUSH study is to assess the effect of therapeutic management guided&#xD;
      by pulmonary ultrasound and the assessment of the inferior vena cava in patients with heart&#xD;
      failure seen in an ambulatory (outpatient) setting on a mixed clinical-biological endpoint&#xD;
      (including variations of natriuretic peptides - NtProBNP) at 30 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives are:&#xD;
&#xD;
      A. To assess the effect of therapeutic management guided by pulmonary ultrasound and inferior&#xD;
      vena cava assessment on the risk of cardiovascular death and hospitalization for heart&#xD;
      failure at 30 days.&#xD;
&#xD;
      B. Describe the proportion of ultrasound congestion (pulmonary and inferior vena cava data)&#xD;
      in patients free from clinical congestion at baseline in the intervention group and in all&#xD;
      patients at D30 visit.&#xD;
&#xD;
      C. Evaluate the association of ultrasound congestion (pulmonary and inferior vena cava&#xD;
      assessment) with serum concentrations of natriuretic peptides at baseline and D30 visit.&#xD;
&#xD;
      D. Evaluate the association of variations in ultrasound congestion (pulmonary and evaluation&#xD;
      of the inferior vena cava) and variations in natriuretic peptides between baseline and D30&#xD;
      visit.&#xD;
&#xD;
      E. Compare the proportion of ultrasound and clinical congestion in patients in the&#xD;
      intervention group and in the control group at baseline and on D30 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">May 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death within 30 days (composite endpoint)</measure>
    <time_frame>Within 30 days</time_frame>
    <description>The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization for heart failure within 30 days (composite endpoint)</measure>
    <time_frame>Within 30 days</time_frame>
    <description>The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in N-terminal pro b-type natriuretic peptide (NtProBNP) between randomization and D30 (composite endpoint)</measure>
    <time_frame>Between randomization and Day 30</time_frame>
    <description>The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>Within 30 days</time_frame>
    <description>Within the combined outcome of CV death or hospitalization for heart failure. Outcomes will be adjudicated blinded from randomization arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound pulmonary congestion defined ≥3 B-lines on two intercostal spaces bilaterally (8-point method) and systemic congestion defined as an inferior vena cava diameter 21 mm or greater and/or a low variation during the respiratory cycle</measure>
    <time_frame>At baseline in the intervention group and in all patients at Day 30 post inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating levels of natriuretic peptides (NtProBNP)</measure>
    <time_frame>At baseline and Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in natriuretic peptides (NtProBNP)</measure>
    <time_frame>Between baseline and Day 30.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound congestion defined as in B / and clinical congestion evaluated according to the EVEREST and ASCEND scores</measure>
    <time_frame>At baseline in the intervention group and in all patients at the Day 30.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual care (i.e. without ultrasound guidance) will be provided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.</intervention_name>
    <description>An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.</description>
    <arm_group_label>Interventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Usual care without ultrasound guidance</intervention_name>
    <description>Usual care (i.e. without ultrasound guidance)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 and over&#xD;
&#xD;
          -  Heart failure (regardless of left ventricular ejection fraction)&#xD;
&#xD;
          -  Diagnosis of heart failure established more than 3 months ago&#xD;
&#xD;
          -  Absence of significant clinical signs of congestion on clinical examination (absence&#xD;
             of crackles and lower limbs oedema greater than perimalleolar oedema)&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
          -  Receiving complete information about research organization and signed informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Natriuretic peptides result, carried out during the previous 30 days, available at the&#xD;
             inclusion consultation&#xD;
&#xD;
          -  Pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound&#xD;
             images: severe emphysema, chronic pleurisy, pulmonary fibrosis.&#xD;
&#xD;
          -  Suspicion of cardiac amyloidosis or proven amyloidosis,&#xD;
&#xD;
          -  Patient with severe primary heart valve disease&#xD;
&#xD;
          -  Pregnant woman, parturient or nursing mother&#xD;
&#xD;
          -  Adult person subject to a legal protection measure (guardianship, curatorship,&#xD;
             safeguard of justice)&#xD;
&#xD;
          -  Person deprived of liberty by a judicial or administrative decision,&#xD;
&#xD;
          -  Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the&#xD;
             Public Health Code.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas GIRERD, MD,PhD</last_name>
    <phone>+33 3 83 15 74 96</phone>
    <phone_ext>+333</phone_ext>
    <email>n.girerd@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-France Seronde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-France Seronde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>David Kenizou, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Kenizou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Nazeyrolas, Md, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Nazeyrolas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR de Metz</name>
      <address>
        <city>Thionville</city>
        <zip>57126</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Noura Zannad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noura Zannad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas GIRERD, MD, PhD</last_name>
      <phone>+33 3 83 15 74 96</phone>
      <phone_ext>+333</phone_ext>
      <email>n.girerd@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas GIRERD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Pr. Nicolas GIRERD</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

